Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques.
复制标题
DOI：
10.1016/j.cell.2022.03.024
复制
发表时间：
2022-04-28
期刊：
影响因子：
64.5
通讯作者：
Barouch DH
中科院分区：
文献类型：
--
作者：
Chandrashekar A;Yu J;McMahan K;Jacob-Dolan C;Liu J;He X;Hope D;Anioke T;Barrett J;Chung B;Hachmann NP;Lifton M;Miller J;Powers O;Sciacca M;Sellers D;Siamatu M;Surve N;VanWyk H;Wan H;Wu C;Pessaint L;Valentin D;Van Ry A;Muench J;Boursiquot M;Cook A;Velasco J;Teow E;Boon ACM;Suthar MS;Jain N;Martinot AJ;Lewis MG;Andersen H;Barouch DH
SARS-CoV-2 Omicron （B.1.1.529）变体的迅速传播，包括在高度接种疫苗的人群中，引发了对当前疫苗有效性的重要质疑。在本研究中，我们展示了基于mrna的BNT162b2疫苗和基于腺病毒载体的Ad26.COV2。S疫苗对食蟹猴的SARS-CoV-2 Omicron变体的高剂量攻击提供了强有力的保护。我们分别用同源和异源的BNT162b2和Ad26.COV2.S接种了30只猕猴。在Omicron攻击后，接种疫苗的猕猴在支气管肺泡灌洗液中表现出对病毒的快速控制，大多数接种疫苗的动物也在鼻拭子中控制了病毒。然而，4只接种疫苗的动物，具有中等的Omicron中和抗体滴度和检测不到的Omicron CD8+ T细胞反应，未能控制上呼吸道的病毒。此外，病毒学控制与抗体和T细胞反应相关。这些数据表明，体液和细胞免疫反应都有助于疫苗保护免受高度突变的SARS-CoV-2变体的侵害。用mRNA疫苗BNT162b2和腺病毒载体Ad26.COV2进行异源和同源引物增强。S疫苗在食蟹猕猴中提供针对SARS-CoV-2 Omicron的强大保护，体液和细胞免疫反应对于整体保护至关重要。
The rapid spread of the SARS-CoV-2 Omicron (B.1.1.529) variant, including in highly vaccinated populations, has raised important questions about the efficacy of current vaccines. In this study, we show that the mRNA-based BNT162b2 vaccine and the adenovirus-vector-based Ad26.COV2.S vaccine provide robust protection against high-dose challenge with the SARS-CoV-2 Omicron variant in cynomolgus macaques. We vaccinated 30 macaques with homologous and heterologous prime-boost regimens with BNT162b2 and Ad26.COV2.S. Following Omicron challenge, vaccinated macaques demonstrated rapid control of virus in bronchoalveolar lavage, and most vaccinated animals also controlled virus in nasal swabs. However, 4 vaccinated animals that had moderate Omicron-neutralizing antibody titers and undetectable Omicron CD8+ T cell responses failed to control virus in the upper respiratory tract. Moreover, virologic control correlated with both antibody and T cell responses. These data suggest that both humoral and cellular immune responses contribute to vaccine protection against a highly mutated SARS-CoV-2 variant. Heterologous as well as homologous prime-boosting with the mRNA vaccine BNT162b2 and adenovirus-vector-based Ad26.COV2.S vaccine provides robust protection against SARS-CoV-2 Omicron in cynomolgus macaques, with both humoral and cellular immune responses being critical for overall protection.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
64.8
作者：
Liu J;Chandrashekar A;Sellers D;Barrett J;Jacob-Dolan C;Lifton M;McMahan K;Sciacca M;VanWyk H;Wu C;Yu J;Collier AY;Barouch DH
通讯作者：
Barouch DH
影响因子：
5.4
作者：
Dagotto, Gabriel;Mercado, Noe B.;Barouch, Dan H.
通讯作者：
Barouch, Dan H.
DOI：
10.1056/nejmoa2101544
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sadoff J;Gray G;Vandebosch A;Cárdenas V;Shukarev G;Grinsztejn B;Goepfert PA;Truyers C;Fennema H;Spiessens B;Offergeld K;Scheper G;Taylor KL;Robb ML;Treanor J;Barouch DH;Stoddard J;Ryser MF;Marovich MA;Neuzil KM;Corey L;Cauwenberghs N;Tanner T;Hardt K;Ruiz-Guiñazú J;Le Gars M;Schuitemaker H;Van Hoof J;Struyf F;Douoguih M;ENSEMBLE Study Group
通讯作者：
ENSEMBLE Study Group
DOI：
10.1126/science.abm3425
发表时间：
2022-01-07
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
通讯作者：
--